Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05976828 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IBRX-042 In Participants With HPV-Associated Tumors

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 3 to 2v8
  2. Primary completion date: Sep 2, 2025 to Sep 2, 2027 Trial status: Recruiting to Active, Not Recruiting · Site details revised at 3 of 3 sitesv7 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
  3. Site contacts updated at 3 of 3 sitesv6
  4. Study sites: 1 to 3 Eligibility criteria shortened, about 91 words · Secondary endpoints: details revised at 1 of 2 entries · Study title revised · 1 morev5 Show 4 more changesShow less
    • Eligibility criteria shortened, about 91 words
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study title revised
    • Study description expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Not Yet Recruiting to Recruiting Enrollment target: 18 to 12 · Primary completion date: Dec 30, 2024 to Sep 2, 2025 · Study sites: 0 to 1v4 Show 3 more changesShow less
    • Enrollment target: 18 to 12
    • Primary completion date: Dec 30, 2024 to Sep 2, 2025
    • Study sites: 0 to 1
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Mar 14, 2024 to Jun 14, 2024v3
  2. Start date: Aug 14, 2023 to Mar 14, 2024v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV) associated tumors. The main questions it aims to answer are: * What is the maximum tolerated dose of IBRX-042? * How well does the study drug treat cancer? * What effects the study drug may have on the human body and cancer? Participants will receive IBRX-042 at one of three dose levels every 3 weeks for a total of 3 injections. Participants will undergo tests, exams, and procedures that are part of standard of care and for study purposes. IBRX-042 will be administered by injection every 3 weeks for a total of 3 injections.
Trial Details
NCT Number NCT05976828
Lead Sponsor ImmunityBio, Inc.
Conditions HPV-Related Carcinoma
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov